Chemical & Engineering News The National Institutes of Health’s flagship long COVID initiative, RECOVER—short for Researching COVID to Enhance Recovery—has after a year of deliberation selected several drug candidates to test as treatments for the condition.
Over the course of a 2-day workshop in Bethesda, Maryland, this week, RECOVER representatives detailed plans to launch clinical trials for several interventions. Those include glucagon-like peptide-1 (GLP-1) drugs, like tirzepatide; stellate ganglion block, a procedure involving the injection of anesthetic into the stellate ganglion nerves to improve circulation; and low-dose naltrexone, a version of a drug for opioid and alcohol use disorders that’s often prescribed off-label for chronic pain.
RECOVER will also allocate additional funding for an ongoing trial of baricitinib, a Janus kinase (JAK) inhibitor made by Eli Lilly and Company that’s approved to treat alopecia and rheumatoid arthritis.